Nový výskum na klinike v Clevelande po prvýkrát ukazuje, že ibrutinib (ibrutinib) schválený FDA pre lymfómy a leukémie môže tiež pomôcť pri liečbe najbežnejších a najsmrteľnejších nádorov mozgu a jedného dňa sa môže používať u pacientov s glioblastómom a zlepšiť mieru prežitia.
Podľa správy American Brain Tumor Association je miera prežitia glioblastómu veľmi nízka a medián prežitia pacientov, ktorí dostávajú štandardnú liečbu, je menej ako 15 mesiacov. Glioblastóm je najsmrteľnejší primárny mozgový nádor a je vysoko odolný voči súčasnej liečbe. Existuje naliehavá potreba poskytnúť týmto pacientom nové spôsoby liečby čo najskôr.
In an earlier study, Bao and colleagues found that glióm stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain nádory in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
